TY -的T1 - 5年生存在急性失代偿性的肺动脉高血压的集现代管理时代的右心衰JF -欧洲呼吸杂志》乔和J - 10.1183/13993003.00466 -2021欧元SP - 2100466 AU Savale Laurent AU - Vuillard,康斯坦斯盟——Pichon杰雷米非盟-仿羔皮呢,Athenais AU -罗氏,安妮盟——Jevnikar Mitja AU -原发,内森盟——洁,泽维尔AU - Le Pavec杰罗姆AU - Montani,大卫•Mercier AU -奥拉夫盟——Sitbon Olivier Fadel,非盟-埃利盟——亨伯特,Marc Y1 - 2021/01/01 UR - //www.qdcxjkg.com/content/early/2021/05/28/13993003.00466 - 2021. -抽象N2 -急性失代偿性的肺动脉高血压(多环芳烃)的特征是右心衰的临床症状迅速恶化(RHF)和随后的拥堵和系统性循环不足可导致多系统器官衰竭[1 - 3]。急性失代偿性的短期结果RHF是非常贫穷的,没有死亡的第一原因多环芳烃(4、5)。重症监护的急性失代偿性的多环芳烃是基于治疗的触发因素,小心液体管理和策略改善心脏功能,减少右心室后负荷[1]。然而,这种医疗策略并不总是足够的恢复持久平衡强加给右心室后负荷及其赔偿能力。耐火RHF尽管最大医疗,机械的使用支持现在应该考虑选择肺移植候选人,或更少通常桥梁复苏患者右侧心脏衰竭的治疗的原因[1]。Veno-arterial体外膜肺氧合(ECMO)是目前使用最广泛的战略支持PAH患者的右心室。这个策略,结合器官分配的变化规则优先短期威胁生命的条件应该有助于改善患者的生存资格终末期患者多环芳烃[6]。然而,长期生存患者在ICU承认对严重急性RHF管理没有得到广泛的研究在现代管理时代的机械支持和高优先级肺移植。FootnotesThis手稿最近发表在《欧洲呼吸杂志》上。这里发表周全之前接受的形式排版,我们的生产团队。这些生产过程完成后,作者已经批准结果证明,本文将最新一期的ERJ在线。 Please open or download the PDF to view this article.Conflict of interest: Dr. Savale reports personal fees from Actelion, personal fees from Bayer, grants and personal fees from GSK, outside the submitted work; .Conflict of interest: Dr. Vuillard has nothing to disclose.Conflict of interest: Dr. Pichon has nothing to disclose.Conflict of interest: Dr. Boucly has nothing to disclose.Conflict of interest: Dr. Roche has nothing to disclose.Conflict of interest: Dr. Jevnikar has nothing to disclose.Conflict of interest: Dr. Ebstein has nothing to disclose.Conflict of interest: Dr. Jais has nothing to disclose.Conflict of interest: Dr. Le Pavec has nothing to disclose.Conflict of interest: Pr. MONTANI reports grants and personal fees from Actelion, grants and personal fees from Bayer, personal fees from GSK, personal fees from Pfizer, grants, personal fees and non-financial support from MSD, personal fees from Chiesi, personal fees from Boerhinger, non-financial support from Acceleron, personal fees from Incyte Biosciences France, outside the submitted work.Conflict of interest: Dr. Mercier has nothing to disclose.Conflict of interest: Dr. SITBON reports grants, personal fees and non-financial support from Actelion Pharmaceuticals, grants and personal fees from Bayer HealthCare, grants and non-financial support from Merck, grants, personal fees and non-financial support from GlaxoSmithKline, personal fees from Arena Pharmaceuticals, outside the submitted work; .Conflict of interest: Dr. Fadel has nothing to disclose.Conflict of interest: Dr. Humbert reports personal fees from Acceleron, grants and personal fees from Actelion, grants and personal fees from Bayer, personal fees from GSK, personal fees from Merck, personal fees from Novartis, personal fees from Astrazeneca, personal fees from Sanofi, outside the submitted work. ER -